2006 Drugs Marketing 
Drug Channels
NOVEMBER 15, 2024
The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies. TThey argue that unified datasets and the addition of AI-driven analytics tools can improve decision making throughout a drug’s life cycle. Read on for their insights.
Drug Channels
JUNE 18, 2025
Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. Below, we share DCI’s latest analysis of the top 15 specialty pharmacies, including updated market shares and revenue estimates. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JULY 15, 2025
Is the gross-to-net bubble —the ever-widening gap between brand-name drug sales at list prices and their net revenues after rebates and discounts—finally beginning to deflate? Drug Channels Institute (DCI) estimates that the gross-to-net reductions for all brand-name drugs reached $356 billion in 2024, a 7% increase over the previous year.
Drug Channels
JULY 22, 2025
It’s time for Drug Channels ’ annual update on drug pricing trends at the largest pharmaceutical manufacturers. These data highlight divergent trends reshaping the gross-to-net bubble: Rebates, discounts, and other fees reduced the selling prices of brand-name drugs at the biggest drugmakers to less than half of their list prices.
Alta Sciences
MARCH 4, 2025
The CCALC is a grassroots organization that was founded by several pharmaceutical industry members seeking clarity around the conduct of abuse and dependence potential assessments for novel drugs in development. This was in 2006, at a time when the FDA guidances on these topics had not yet been published.
Drug Target Review
JUNE 2, 2025
Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. The addition of Drug Product assets for cytotoxic substances completes the fully integrated offering.
Drug Patent Watch
JANUARY 13, 2025
As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1].
Expert insights. Personalized for you.
98 
Let's personalize your content